You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Pfizer
since
auto-detected in 69 stories
29 days ago
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
30 days ago
Novo Nordisk again raises bid in battle for obesity start-up Metsera
found
a story from Financial Times ✅ › Financial Times
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
31 days ago
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount ⊖
found
a story from CNBC ⚠️ › World News
Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
32 days ago
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk ⊖⊖
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies
Improved pitches from both large pharma groups expected to be revealed later on Tuesday
Pfizer tops estimates, raises profit guidance even as sales fall ⊕⊕
Pfizer hiked its full-year profit guidance, citing its strong business performance and cost cuts, even as sales for the period fell.
33 days ago
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech ⊖⊖
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.